Form D · Biotechnology
Molecular Templates, Inc.
Austin, TX · CIK 0001183765
Offering snapshot reported Jul 31, 2023 · SEC filing
- Reported sold
- $20M Offering amount: $90.7M
- Investors reported
- 19 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jul 17, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 31, 2023 | Initial | $19,999,998 | No comparison | 19 | SEC filing |
| Dec 3, 2019 | Amendment | $14,999,994 | $0vs Nov 27, 2019 | 1 | SEC filing |
| Nov 27, 2019 | Initial | $14,999,994 | No comparison | 1 | SEC filing |
| Aug 15, 2017 | Initial | $40,000,000 | No comparison | 16 | SEC filing |
| Aug 15, 2017 | Initial | $20,000,000 | No comparison | 1 | SEC filing |
| Oct 15, 2009 | Initial | $35,000,000 | No comparison | 47 | SEC filing |
| Sep 12, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $2.7M (estimated)
- Finders' fees
- $0
- Form D file number
- 021-488378
Total offering amount includes the $0.125 per underlying share of common stock for warrants to purchase common stock to be issued in a second closing, assuming certain conditions are met, and the aggregate exercise price of such warrants.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Stifel, Nicolaus & Company, Incorporated | 793 |
Source: Form D, filed Jul 31, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Jeffrey W. Bird | Director |
| Michael Broxson | Director |
| Bruce C. Cozadd | Director |
| John G. Curd | Executive |
| Adam D. Cutler | Executive |
| Joel A. Fernandes | Executive |
| Gabriela Gruia | Director |
| William A. Halter | Director |
| David Hirsch | Director |
| David Hoffman | Director |
| David Hoffmann | Director |
| Wilfred E. Jaeger | Director |
| Jason Kim | Executive |
| Stewart M. Kroll | Executive |
| Kevin Lalande | Director |
| Jonathan Lanfear | Director |
| Mark D. Matteucci | Executive |
| Scott Morenstein | Director |
| Eric E. Poma | Director, Executive |
| Eric Rogers | Executive |
| Corsee Sanders | Director |
| Harold E. Selick | Director |
| David Valacer | Executive |
| Roger J. Waltzman | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
9301 Amberglen Blvd Suite 100
Austin, TX, 78729
Austin, TX, 78729